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Summary
Objective: To assess the efﬁcacy of selenium supplementation for prevention of Kashin-Beck Osteoarthropathy in children.
Methods: We searched eight electronic databases and seven journals (upto July 2007) to identify randomized controlled trials (RCTs) and
prospective non-RCTs comparing selenium supplementations with placebo or no intervention for preventing Kashin-Beck disease (KBD).
The methodological qualities of included studies were assessed according to the guidelines of Cochrane Handbook for Systematic Reviews
of Interventions for RCTs and the method described by Deeks et al. for non-RCTs. Outcomes were presented as Peto-odds ratios (Peto-ORs)
with 95% conﬁdence intervals (95% CIs) based on ﬁxed effect model. The number needed to treat (NNT) was calculated. Meta-regression was
also conducted to explore the possible impacts of potential confounding variables (place of study, age, selenium form, etc.) of included trials
on the incidence of KBD.
Results: Five RCTs and 10 non-RCTs were included in this review. The methodological quality of included studies was low. The pooled Peto-
OR and NNT favoring selenium supplement was 0.13 (95% CI: 0.04e0.47) and 21 in RCTs, and 0.16 (95% CI: 0.09e0.30) and 26 in non-
RCTs. Meta-regression indicated that the effect of potential confounding variables on KBD incidence was not statistically signiﬁcant. One trial
reported the side effects of nausea and vomiting in the process of selenium supplementation.
Conclusions: Current evidence supports the beneﬁts of selenium supplementation for prevention of KBD in children. However, the evidence
was limited by potential biases and confounders. Large, well-designed trials are still needed.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Kashin-Beck osteoarthropathy (Kashin-Beck disease, KBD)
is an undeﬁned chronic disease involving growth and joint
cartilage1e3. The worst forms of the disease tend to start in
childhood and may result in dwarﬁsm. Affected individuals
present with joint destruction, which produces recurrent
and mainly bilateral joint pain, with restriction of movement
and metaphysical enlargement4e7. This disease is widely
distributed in China from Heilongjiang in the northeast to
Sichuan and Tibet in the southwest, involving 15 provin-
ces8e10. The prevalence of KBD is reported to be
8.0e43.4% in heavily affected sites11e15.
The trace element selenium is an essential component of
a number of selenoproteins. These include glutathione per-
oxidases (a family of enzymes that protect against oxidative
injury by catalyzing the breakdown of hydrogen peroxide
and lipid hydroperoxides); iodothyronine deiodinase (which*Address correspondence and reprint requests to: Dr Guanjian
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144converts thyroxine [T4] to 3,5,30-triodothyronine [T3]); and
thioredoxin reductase (which is a key enzyme regulating
the redox state of cells)16e18.
Selenium deﬁciency has been long suggested as an
etiological factor for KBD and Keshan cardiomyopathy (Ke-
shan disease, KSD)19e21. Epidemiological studies revealed
signiﬁcant selenium deﬁciency in the KBD and KSD endemic
areas compared to normal regions22e26. Animal experiment
showed that combined selenium and iodine deﬁciency could
impair the growth of bone and cartilage27 and the growth
retardation induced by selenium deﬁciency is associated
with impaired bone metabolism and osteopenia28. Evidence
from some other epidemiological studies and animal experi-
ments, however, conﬂicts with this hypothesis that selenium
deﬁciency was associated with KBD29e32.
The efﬁcacy of selenium supplementation for the primary
prevention of KBD in children is also uncertain. Either clin-
ical controlled trials or randomized controlled trials (RCTs)
investigating whether selenium supplements may prevent
KBD have been inconclusive. A bibliographic analysis
was conducted by Allander33 in 1992, which made a histor-
ical prospect of KBD researches. However, the evidence
has not been systematically appraised.
The objective of this meta-analysis was to synthesize the
results from RCTs as well as non-RCTs to assess the efﬁ-
cacy of selenium supplementation for primary prevention of
KBD in children living in geographically low selenium areas.
145Osteoarthritis and Cartilage Vol. 17, No. 2Materials and methodsINCLUSION AND EXCLUSION CRITERIAWe included RCTs and prospective non-RCTs comparing the efﬁcacy of
selenium supplementation with no treatment or placebo for preventing KBD
in children (under 18 years of age). Studies reporting mixed groups of partic-
ipants (e.g., children with and without KBD) were also included only if data
could be identiﬁed separately for the prevention effect. Selenium supplemen-
tation combined with vitamin E, vitamin C or both was excluded. There were
no restrictions on the administration route and duration.SEARCH STRATEGYWe searched the following electronic databases: Cochrane Central
Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3,
2007), MEDLINE (1966eJuly 2007), EMBASE (1983eJuly 2007), CBM (The
Chinese Biomedical Database, 1978eJuly 2007), CNKI (Chinese National
Knowledge Infrastructure, 1979eJuly 2007), VIP (Chinese Science and Tech-
nique Journals Database, 1989eJuly 2007), Chinese Clinical Trial Register
(http://www.cjebm.org.cn/chictr/information. html) and Clinical Trials.gov
(www.clinicaltrials.gov). The search was performed by using ‘‘Kashin-Beck
disease’’, ‘‘Kaschin-Beck disease’’, ‘‘Urov’’ and ‘‘selenium’’, combined with
MeSH terms and text words. No language restriction was added.
We also handsearched the reference lists of included studies as well as
the following journals: International Orthopaedics, Chinese Journal of Ortho-
paedics, Chinese Journal of Endemic Disease, Chinese Journal of Control of
Endemic Disease, Chinese Journal of Epidemiology, Chinese Journal of Pre-
ventive Medicine and Studies of Trace Elements and Health from the earliest
record to July 2007.STUDY IDENTIFICATIONTwo reviewers (GJ L and K Z) identiﬁed studies independently in two
stages. Firstly, titles and abstracts were assessed; studies were excluded
if they had an obvious violation of the inclusion criteria. Then full text were
obtained and assessed to determine the inclusion of potentially eligible stud-
ies. Any disagreement was resolved by consensus.METHODOLOGICAL QUALITY EVALUATIONThe methodological quality of included RCTs was accessed according to
the guidelines of Cochrane Handbook for Systematic Reviews of Interven-
tions 4.2.534 and the description provided by Wu and Liu35 for each of the
following items: (1) randomization; (2) allocation concealment; (3) blinding
method; and (4) follow-up. A checklist described by Deeks et al.36 was
used to assess the methodological quality of prospective non-RCTs. Any
disagreement was resolved by consensus.DATA SYNTHESISData analyses were conducted by Review Manager version 4 (The
Nordic Cochrane Centre, The Cochrane Collaboration, 2003) and StataPUBMED 154 
EMBASE 137 
Title scan exclude: review, 
animal research, laboratory
experiment, epidemiological 
survey, annual report from 
health administration (n=864)
Citation 1060
Eligible studies (
Citation 196
CENTRAL 3 
Fig. 1. Flow chart of studyversion 9 (STATA Corp, College Station, TX). The efﬁcacy of selenium sup-
plementation for preventing KBD was presented as Peto-odds ratios (Peto-
OR) with 95% conﬁdence intervals (CIs). The number needed to treat
(NNT) was also calculated. A ‘ﬁxed-effect’ approach was used when no sig-
niﬁcant heterogeneity was identiﬁed; or else a ‘random-effect’ statistical
model was used. Test for heterogeneity was carried out by using Chi-square
(c2) test with signiﬁcance being set at a P value <0.1. I 2 was used to esti-
mate the total variation across studies. I 2 higher than 50% was considered
as substantial heterogeneity37.
RCTs and non-RCTs were analyzed separately, for their hetero-method-
ology and different strengths in controlling the play of chance and confound-
ing factors.
We also used meta-regression in the analysis to explore the potential
impact of study design, start year, region, administration route and duration
of follow-up on the incidence of KBD.Results
We accessed 1060 citations through the search strategy.
Finally, 5 RCTs and 10 prospective non-RCTs were
included in this review. And 2216 participants were involved
in the meta-analyses. All trials were conducted in China
from1982 to 1994andpublished inChinese language (Fig. 1)CHARACTERISTICS OF RCTs (TABLE I)Two40,42 RCTs reported identical data in terms of place,
participants and outcomes, which seemed to be a same
trial. Thus, the data were used in meta-analysis only once.
Participants
Participants of all ﬁve trials were children in the KBD
endemic regions, including children with and without KBD.
The age range of participants was 3e13 years. The total
number of healthy children involved was 529.
Intervention
All the includedRCTs used selenium tablets as intervention
and placebo as control except for one trial41, which did not
present the details of intervention and control. One trial40 com-
pared two regimens of seleniumsupplementation with control.
Outcomes
One study reported each year’s KBD incidence rates41,
the other four studies reported the case number ofCBM 378 
CNKI 173 
VIP 188 
Hand search 23 
Other source 1 
Abstract and full text reading 
exclude: retrospective study, 
study with no control or other 
intervention (n=110) 
Paper can not be accessed 
(n=24)  
Duplication (n=47) 
 
n=15) 
 
selection process.
Table I
Characteristics of included trials
Study Design Participants Case number Intervention Control Outcome Follow-up
(yrs)
Diagnosis
criteria
I C
YSSG38 Randomized
matching
Children
3e13 yrs
38 30 Sodium selenite tablet, 1 mg/week
(3e10 yrs), 2 mg/week (11e13 yrs)
Placebo/week Case number,
T: 0, C: 0
1 X-ray, criteria of YSSG
Niu et al.39 Randomized
stratiﬁed
Children
6e13 yrs
13 10 Sodium selenite tablet ﬁrst week:
1.0 mg/day (below 10 yrs), 2.0 mg/day
(above 11 yrs); after: 1.0 mg/week (below
10 yrs), 2.0 mg/week (above 11 yrs)
Placebo/week Case number,
T: 0, C: 3
2 X-ray
Niu et al.40 Randomized
stratiﬁed
Children
6e13 yrs
Ia100,
Ib38
Ca136,
Cb47
Sodium selenite tablet, Ia,Ib: 1.0 mg/day
(below 10 yrs), 2.0 mg/day
(above 11 yrs); after: Ia: 1.0 mg/week (below
10 yrs), 2.0 mg/week (above 11 yrs);
Ib: 2.0 mg/month (below 10 yrs),
4.0 mg/month (above 11 yrs)
Placebo/week Case number,
Ia: 0, Ib: 0, Ca:
3, Cb: 4
1 X-ray
Deng41 Randomized
matching
Children
2e13 yrs
53 77 Sodium selenite, no details Unclear Incidence of KBD
each year
3 X-ray, YSSG criteria
Niu et al.42 Randomized
stratiﬁed
Children
6e13 yrs
38 47 Sodium selenite, ﬁrst week: 0.5 mg/day
(below 5 yrs), 1.0 mg/day
(6e10 yrs), 2.0 mg/day (above 11 yrs); after:
1.0 mg/month (below 5 yrs), 2.0 mg/month
(6e10 yrs), 4.0 mg/month (above 11 yrs)
Placebo/month Case number,
T: 0, C: 3
1 X-ray
Wang et al.43 Control,
prospective
Children
6e13 yrs
21 41 Sodium selenite salt, estimated
97e121 mg/day
Placebo Case number,
T: 0, C: 4
10/12 Criteria of YSSG
Zhou et al.49 Control,
prospective
Children 62 49 Seleniumeiodine salt UC Case number,
T: 1, C: 2
4 X-ray
Ding et al.44 Control,
prospective
Children
below 13 yrs
UC UC Sodium selenite solution spraying on the
surface of crops; 0.8 g/mu for wheat,
1.0 g/mu for corn
UC Case number,
T: 0, C: 1
3 X-ray of hand
Wu45 Control,
prospective
Children
5e16 yrs
34 46 Sodium selenite tablet, 1 mg/week
(below 10 yrs), 2 mg/week (above 10 yrs)
Placebo/week Case number,
T: 0, C: 13
1 Criteria of
Heilongjiang (1980)
Cheng and Zhu46 Control,
prospective
Children
7e15 yrs
119 117 Sodium selenite salt with 60,000:1
concentration, but replaced by sodium selenite
tablet (1e2 mg/week) in some participants.
The number of participants who received
sodium selenite tablet was unclear
NT Case number,
T: 1, C: 2
1 X-ray of right hand
He et al.47 Control,
prospective
Children
3e13 yrs
UC UC Sodium selenite tablet, 1 mg/week
(3e10 yrs), 2 mg/week (11e13 yrs)
UC Case number,
T: 0, C: 2
3 National criteria (1983.9)
Wang et al.48 Control,
prospective
Children
6e13 yrs
214 179 Well water containing rich selenium NT Case number,
T: 0, C: 2 (man-year)
6 National criteria
Ding50 Control,
prospective
Children
2e6 yrs
157 90 Sodium selenite salt with 60000:1 concentration UC Case number,
T: 2, C: 6
4 X-ray
Li et al.51 Control,
prospective
Children
3e14 yrs
300 264 Fertilizer contained selenium (0.05%) for wheat,
sodium selenite: 10e20/mu in Feb 1987
UC Case number,
T: 0, C: 4
1 X-ray
Zhou et al.52 Control,
prospective
Children
4e14 yrs
52 72 Sodium selenite tablet, 1 mg/week (below
10 yrs), 2 mg/week (above 10 yrs)
Placebo/week Case number,
T: 0, C: 4
2 X-ray
yrs¼ years, I¼ intervention, C¼ control, YSSG¼Yongshou scientiﬁc survey group of KBD, 1 mu¼ 666.67 m2, UC¼ unclear, NT¼ no treatment.
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Table II
Methodological quality of included RCTs
Study Generation
of random
sequence
Allocation
concealment
Blinding
method
Loss to
follow-up
YSSG38 UC NM Double-blind No
Niu et al.39 UC NM Double-blind UC
Niu et al.40 UC NM Not used No
Deng41 UC NM Double-blind UC
Niu et al.42 UC NM Double-blind No
YSSG¼Yongshou scientiﬁc survey group of KBD,
UC¼ unclear, NM¼ not mentioned.
147Osteoarthritis and Cartilage Vol. 17, No. 2KBD38e40,42. Two studies discussed the safety of selenium
supplementation39,42.
Duration of follow-up
The duration of follow-up of included RCTs ranged from
1 to 3 years.CHARACTERISTICS OF NON-RCTs (TABLE I)Participants
Participants were children in the KBD endemic regions.
The age range of participants was 0e16 years. The total
number of healthy children involved was 1817. One study44
did not describe the age of included children.
Intervention
Selenium salt was used as intervention by two trials43,50,
and selenium tablet was used by three trials46,48,52.
Seleniumeiodine salt, spraying selenium liquor on crops,
selenium water and applying fertilizer containing selenium
was used by one trial, respectively44,45,49,51. One trial47
was designed to use selenium salt, but ﬁnally selenium
tablet was substituted in some participants due to poor
compliance.
Control
Three trials43,46,52 used placebo, while the others had
either no description or no treatment for control.
Outcomes
All the trials reported the number of KBD patients or
incidence of KBD. No other outcomes directing against
the efﬁcacy of primary prevention were presented.
Duration of follow-up
The duration of follow-up of included non-RCTs ranged
from 10 months to 6 years.METHODOLOGICAL QUALITY OF RCTs (TABLE II)Generation of random sequence
No included RCTs presented the details on how the
sequence was generated. Four trials mentioned stratiﬁed
randomization by X-ray-based disease progression39e42.
And one trial mentioned the use of matching before ran-
domization, by gender, age and disease progression of
participants38.Allocation concealment
None of the included RCTs mentioned allocation
concealment in any form.
Blinding method
Four trials38,39,41,42 used double-blinding, but to whom
the blinding method referred was unclear.
Completeness of follow-up
Three trials38,40,42 had no loss to follow-up. None used
intention-to-treat analysis.METHODOLOGICAL QUALITY OF NON-RCTs (TABLE III)How the allocation occurred
Eight trials described how the allocation occur-
red43,45,47e52. One of them used cluster in the process of
group generation45. Seven trials recruited children of the
neighboring village to be the control group44,47e52.
Baseline assessment
Seven trials assessed the comparability of geographical
selenium concentration (in water, soil or grain) or preva-
lence of KBD between regions where groups were crea-
ted43,47e52. One trial also assessed the comparability of
age between groups52.
Identification of confounders and prognostic factors
One study used standardized age for analysis48.
Blinding
One study mentioned the use of double-blinding to partic-
ipants and observers, however, whether X-ray readers were
blinded was unclear46.
Completeness of follow-up
Five trials had no loss to follow-up43,44,46,51,52. No trial
mentioned the use of intention-to-treat analysis.
Statistical method
None of the 10 trials provided enough information about
the statistical method used.META-ANALYSIS OF RCTs [FIG. 2(A)]For RCTs, the pooled Peto-OR favoring selenium supple-
ment was 0.13 (95% CI: 0.04e0.47), which indicated a sig-
niﬁcant difference in efﬁcacy between selenium
supplementation and control. The NNT was 21. No hetero-
geneity was identiﬁed among different trials (c2¼ 0.23,
P¼ 0.89, I2¼ 0%).META-ANALYSIS OF NON-RCTs [FIG. 2(B)]For non-RCTs, the pooled Peto-OR favoring selenium
supplement was 0.16 (95% CI: 0.09e0.30), which indicated
a signiﬁcant difference in efﬁcacy between selenium supple-
mentation and control. The NNT was 26. No heterogeneity
Table III
Methodological quality of non-RCTs
Wang et al.43 Zhou49 Ding et al.44 Wu45 Cheng and Zhu46 He et al.47 Wang et al.48 Ding50 Li et al.51 Zhou et al.52
1 Generation of groups
1.1 How allocation occurred NA UC Cluster UC NA NA NA NA NA NA
1.2 Balance groups by design No No No No No No No No No No
2 Blinding
2.1 Blind (or double-blind)
administration
No No No Yes No No No No No No
2.2 Blind outcome assessment No No No No No No No No No No
3 Ascertainment
3.1 Receipt of the intervention Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
3.2 Attributable outcomes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4 Follow-up
4.1 Equal follow-up
between groups
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4.2 Completeness of follow-up Yes Yes UC Yes No No No UC Yes Yes
5 Comparability
5.1 Baseline comparability
assessed
Se in water,
soil, wheat, hair
No No No Prevalence;
geography
Prevalence Prevalence;
Se in soil, water
Mentioned,
no details
Prevalence;
Se in soil, wheat
Prevalence;
age
5.2 Prognostic factors identiﬁed No No No No No No No No No No
5.3 Case-mix adjustment No No No No No Yes No No No No
6 Analysis
6.1 Intention-to-treat analysis No No No No No No No No No No
6.2 Appropriate analysis
methods
UC UC UC UC UC UC UC UC UC UC
NA¼ neighboring areas, Se¼ selenium, UC¼ unclear.
1
4
8
K
.
Z
o
u
e
t
a
l.:
S
e
le
n
iu
m
fo
r
K
B
D
p
re
v
e
n
tio
n
in
c
h
ild
re
n
Fig. 2. Meta-analysis of selenium supplementation vs control for primary prevention of KBD.
149Osteoarthritis and Cartilage Vol. 17, No. 2was observed among different trials (c2¼ 3.45, P¼ 0.84,
I2¼ 0%).META-REGRESSIONWe conducted meta-regression to explore the potential
impact of study design, start year, region, administration
route and duration of follow-up on the efﬁcacy of selenium
supplementation. No signiﬁcant effects were demonstrated.
We used each region and administration route as control in
meta-regressions, and found similar outcomes to those
from the prior analysis.ADVERSE EVENTSTwo RCTs and one non-RCT discussed the safety of
selenium supplementation. One trial mentioned that
‘‘some participants had nausea and vomiting at the begin-
ning of the trial’’42, but did not present further details. The
other two trials described that no adverse event was
observed39,48.Discussion
The pooled results from RCTs or non-RCTs were similar
and demonstrated the beneﬁts of selenium supplementationfor the primary prevention of KBD in children. Current evi-
dence revealed no substantial effect of trial design, start
year, region, administration route and duration of follow-up
on the incidence of KBD. However, several factors must be
taken into consideration when interpreting the results, for
their potential inﬂuences on the outcomes.
The overall methodological quality of included studies
was low. For RCTs, the process and method used to gen-
erate random sequence was not clear in all ﬁve trials. And
allocation concealment was not mentioned by any of
them. Four studies used double-blinding, but to whom the
blinding method referred was unclear (blinding to the X-
ray reader is considered as the most important and sufﬁ-
cient way in this review). Selection bias and detection
bias may be induced in these RCTs. For the 10 non-
RCTs, few of them sufﬁciently assessed the baseline
characteristics of participants (e.g., age, gender, socioeco-
nomic status and geographical selenium intake, etc).
None but one trial mentioned blinding. Loss to follow-up
was unclear in seven trials. Nine trials did not make any
adjustment for potential confounders and important diag-
nostic factors of KBD (e.g., age, socioeconomic status,
etc). Therefore, selection bias, detection bias, attrition bias
and confounders may exist in these non-RCTs.
Additionally, the sample sizes of most trials on selenium
supplementation were relatively small. Sample size calcula-
tion was not mentioned in any of them. Duration of follow-up
150 K. Zou et al.: Selenium for KBD prevention in childrenvaried from 10 months to 6 years. Quite a few trials had
obviously insufﬁcient duration of follow-up for such a chronic
disease, though the most favorable duration is still uncer-
tain. The small sample size and insufﬁcient duration of
follow-up may be responsible for potential biases in these
trials.
The recommended daily intake of selenium for adults
(age 18) is 55 mg/day, and the upper limit (UL) for adults
is 400 mg/day. The recommended daily intake of selenium
for children increases with age, from 15 mg/day (age <0.5)
to 50 mg/day (age 14). And the UL of selenium also
increases with age, from 55 mg/day (age <0.5) to 400
mg/day (age 14)53e59. The tablets of sodium selenite sup-
plementation dosed from 0.5 to 4 mg/week, which were
used by many included trials, may result in excessive sele-
nium status and subsequent adverse events such as nau-
sea, vomiting, hair loss or nail loss, etc.
However, except for incidence, few trials reported side
effects and other important outcomes related to the primary
prevention of KBD. Data were insufﬁcient to examine the
adverse effects of selenium supplementation and impact
of dosage on the outcomes.
Methodological quality of included trials was not
accessed with blinding to the authors and institutions.ConclusionsIMPLICATIONS FOR PRACTICECurrent evidence from RCTs and non-RCTs consistently
suggests the beneﬁts of selenium supplementation for the pri-
mary prevention of KBD in children. Nevertheless, the evi-
dence may be limited by potential biases and confounders,
and more evidence from trials of high quality is needed.IMPLICATIONS FOR RESEARCHLarge, well-designed trials are required. It is suggested
that healthy children (without KBD at the start of trials)
be recruited and followed for a sufﬁcient period of time.
Cluster-randomization should be implemented on at least
20 samples at village, school or classroom level60. Alloca-
tion concealment should be adequately implemented.
Blinding should be used in at least participants and X-
ray radiologists. Besides, the dosage and administration
route of selenium supplementation should be well-deﬁned.
Monitoring of treatment (placebo and selenium supple-
ment) should be conducted using biomarkers like selenium
concentration of hair or urine. And a standardized diagnos-
tic criterion of KBD involving both clinical and X-ray
manifestations should be applied61e63. More details on
adverse effects, growth, joint pain and grade of motion
restriction should be measured and presented. Finally,
the reporting of any future trials should conform to the
CONSORT statement64.Conﬂict of interest
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